Author Correction: Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial

Saad Z Usmani¹, Thierry Facon², Vania Hungria³, Nizar J Bahlis⁴, Christopher P Venner^{5

6}, Marc Braunstein⁷, Ludek Pour⁸, Josep M Martí⁹, Supratik Basu¹⁰, Yael C Cohen^{11

12}, Morio Matsumoto¹³, Kenshi Suzuki¹⁴, Cyrille Hulin¹⁵, Sebastian Grosicki¹⁶, Wojciech Legiec¹⁷, Meral Beksac¹⁸, Angelo Maiolino^{19

20}, Hiroyuki Takamatsu²¹, Aurore Perrot²², Mehmet Turgut²³, Tahamtan Ahmadi²⁴, Weiping Liu²⁵, Jianping Wang²⁶, Katherine Chastain²⁷, Jessica Vermeulen²⁸, Maria Krevvata²⁶, Lorena Lopez-Masi²⁷, Jodi Carey²⁶, Melissa Rowe²⁹, Robin Carson²⁶, Sonja Zweegman³⁰

Affiliations

¹ Memorial Sloan Kettering Cancer Center, New York, NY, USA. usmanis@mskcc.org.
² University of Lille, CHU de Lille, Service des Maladies du Sang, Lille, France.
³ Clínica Médica São Germano, São Paulo, Brazil.
⁴ Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, Alberta, Canada.
⁵ Department of Medical Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada.
⁶ BC Cancer-Vancouver Centre, University of British Columbia, Vancouver, British Columbia, Canada.
⁷ Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA.
⁸ University Hospital Brno, Brno, Czech Republic.
⁹ Hospital Universitario Mútua de Terrassa, Terrassa, Spain.
¹⁰ Royal Wolverhampton NHS Trust and University of Wolverhampton, CRN West Midlands, National Institute for Health and Care Research, Wolverhampton, UK.
¹¹ Department of Hematology, Tel Aviv Sourasky (Ichilov) Medical Center, Tel Aviv, Israel.
¹² Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
¹³ Department of Hematology, National Hospital Organization Shibukawa Medical Center, Gunma, Japan.
¹⁴ Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan.
¹⁵ Department of Hematology, Hôpital Haut Lévêque, University Hospital, Pessac, France.
¹⁶ Department of Hematology and Cancer Prevention, School of Public Health, Medical University of Silesia, Katowice, Poland.
¹⁷ Department of Hematology and Bone Marrow Transplantation, St. John of Dukla Oncology Center of Lublin Land, Lublin, Poland.
¹⁸ Istinye University, Ankara Liv Hospital, Ankara, Turkey.
¹⁹ Instituto Americas de Ensino, Pesquisa e Inovação, Rio de Janeiro, Brazil.
²⁰ Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
²¹ Department of Hematology, Kanazawa University Hospital, Kanazawa University, Kanazawa, Japan.
²² CHU de Toulouse, IUCT-O, Université de Toulouse, UPS, Service d'Hématologie, Toulouse, France.
²³ Department of Hematology, Ondokuz Mayıs University Faculty of Medicine, Samsun, Turkey.
²⁴ Genmab US, Inc., Plainsboro, NJ, USA.
²⁵ Johnson & Johnson, Shanghai, China.
²⁶ Johnson & Johnson, Spring House, PA, USA.
²⁷ Johnson & Johnson, Raritan, NJ, USA.
²⁸ Johnson & Johnson, Leiden, The Netherlands.
²⁹ Johnson & Johnson, High Wycombe, UK.
³⁰ Department of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands.

PMID: 39948407
PMCID: PMC12003187
DOI: 10.1038/s41591-025-03581-2

Published Erratum

Author Correction: Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial

Saad Z Usmani et al. Nat Med. 2025 Apr.

. 2025 Apr;31(4):1366.

doi: 10.1038/s41591-025-03581-2.

Authors

Affiliations

¹ Memorial Sloan Kettering Cancer Center, New York, NY, USA. usmanis@mskcc.org.
² University of Lille, CHU de Lille, Service des Maladies du Sang, Lille, France.
³ Clínica Médica São Germano, São Paulo, Brazil.
⁴ Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, Alberta, Canada.
⁵ Department of Medical Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada.
⁶ BC Cancer-Vancouver Centre, University of British Columbia, Vancouver, British Columbia, Canada.
⁷ Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA.
⁸ University Hospital Brno, Brno, Czech Republic.
⁹ Hospital Universitario Mútua de Terrassa, Terrassa, Spain.
¹⁰ Royal Wolverhampton NHS Trust and University of Wolverhampton, CRN West Midlands, National Institute for Health and Care Research, Wolverhampton, UK.
¹¹ Department of Hematology, Tel Aviv Sourasky (Ichilov) Medical Center, Tel Aviv, Israel.
¹² Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel.
¹³ Department of Hematology, National Hospital Organization Shibukawa Medical Center, Gunma, Japan.
¹⁴ Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan.
¹⁵ Department of Hematology, Hôpital Haut Lévêque, University Hospital, Pessac, France.
¹⁶ Department of Hematology and Cancer Prevention, School of Public Health, Medical University of Silesia, Katowice, Poland.
¹⁷ Department of Hematology and Bone Marrow Transplantation, St. John of Dukla Oncology Center of Lublin Land, Lublin, Poland.
¹⁸ Istinye University, Ankara Liv Hospital, Ankara, Turkey.
¹⁹ Instituto Americas de Ensino, Pesquisa e Inovação, Rio de Janeiro, Brazil.
²⁰ Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
²¹ Department of Hematology, Kanazawa University Hospital, Kanazawa University, Kanazawa, Japan.
²² CHU de Toulouse, IUCT-O, Université de Toulouse, UPS, Service d'Hématologie, Toulouse, France.
²³ Department of Hematology, Ondokuz Mayıs University Faculty of Medicine, Samsun, Turkey.
²⁴ Genmab US, Inc., Plainsboro, NJ, USA.
²⁵ Johnson & Johnson, Shanghai, China.
²⁶ Johnson & Johnson, Spring House, PA, USA.
²⁷ Johnson & Johnson, Raritan, NJ, USA.
²⁸ Johnson & Johnson, Leiden, The Netherlands.
²⁹ Johnson & Johnson, High Wycombe, UK.
³⁰ Department of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, The Netherlands.

PMID: 39948407
PMCID: PMC12003187
DOI: 10.1038/s41591-025-03581-2

No abstract available

PubMed Disclaimer

Erratum for

Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial.
Usmani SZ, Facon T, Hungria V, Bahlis NJ, Venner CP, Braunstein M, Pour L, Martí JM, Basu S, Cohen YC, Matsumoto M, Suzuki K, Hulin C, Grosicki S, Legiec W, Beksac M, Maiolino A, Takamatsu H, Perrot A, Turgut M, Ahmadi T, Liu W, Wang J, Chastain K, Vermeulen J, Krevvata M, Lopez-Masi L, Carey J, Rowe M, Carson R, Zweegman S. Usmani SZ, et al. Nat Med. 2025 Apr;31(4):1195-1202. doi: 10.1038/s41591-024-03485-7. Epub 2025 Feb 5. Nat Med. 2025. PMID: 39910273 Free PMC article. Clinical Trial.

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Nature Publishing Group
- PubMed Central

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Author Correction: Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial

Affiliations

Author Correction: Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial

Authors

Affiliations

Erratum for

Publication types

LinkOut - more resources

Full Text Sources